Related Experiment Video

Updated: May 17, 2026

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

Post-marketing surveillance of levofloxacin 0.5% ophthalmic solution for external ocular infections

Yoshiko Kanda1, Tomoko Kayama, Shinji Okamoto

  • 1Post-Marketing Surveillance Group, Santen Pharmaceutical Co., Ltd., Osaka, Japan.

Drugs in R&D
|October 19, 2012
PubMed
Abstract

Insights

Levofloxacin 0.5% ophthalmic solution demonstrated excellent safety and efficacy in treating external ocular bacterial infections in a large-scale Japanese post-marketing study. The antibacterial eye drop showed a high clinical response rate with minimal adverse drug reactions.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Pharmacology

Background:

  • Levofloxacin 0.5% ophthalmic solution, an antibacterial agent, was approved in Japan in 2000 for treating ocular infections.
  • This formulation is widely used in clinical practice for various eye conditions.

Purpose of the Study:

  • To evaluate the safety and efficacy of levofloxacin 0.5% ophthalmic solution in routine clinical settings.
  • To assess the drug's performance in a large patient cohort across Japan.

Main Methods:

  • Post-marketing surveillance involving 6760 patients across over 800 medical facilities in Japan.
  • Data collection occurred over three distinct periods from April 2000 to December 2004.
  • Adherence to Japanese Ministry of Health, Labour and Welfare guidelines ensured study integrity.

Main Results:

  • Levofloxacin was well-tolerated, with a low incidence of adverse drug reactions (0.63%) and no serious events reported.
  • Common adverse drug reactions included blepharitis, eye irritation, and punctate keratitis, with higher incidence in females.
  • A high overall clinical response rate of 95.5% was observed, with variations based on specific bacterial infections and patient factors.

Conclusions:

  • Post-marketing surveillance confirms the safety and efficacy of levofloxacin 0.5% ophthalmic solution in real-world clinical use.
  • Levofloxacin is a valuable and promising therapeutic option for diverse external ocular bacterial infections.
  • The study supports the continued use of levofloxacin for managing bacterial eye infections.

More Related Videos

Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes09:20

Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes

Published on: February 8, 2018

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Microbiome of the Eye01:22

Microbiome of the Eye

The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...